CSL (OTCMKTS:CSLLY) Reaches New 12-Month Low – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) hit a new 52-week low on Tuesday . The stock traded as low as $16.01 and last traded at $17.26, with a volume of 334195 shares trading hands. The stock had previously closed at $17.08.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CSLLY. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Citigroup cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Zacks Research cut CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Canaccord Genuity Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce”.

CSL Price Performance

The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. The company has a 50 day simple moving average of $21.14 and a 200-day simple moving average of $40.95.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.